{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:24:46Z","timestamp":1770816286752,"version":"3.50.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec id=\"ab-eoi230065-4\"><jats:title>Importance<\/jats:title><jats:p>Intra-arterial chemotherapy (IAC) has quickly gained popularity as a mainstay of treatment for retinoblastoma. Intra-arterial chemotherapy has been described as having several advantages over systemic chemotherapy, including reducing systemic toxicity and neutropenia; however, studies on the risk of neutropenia after IAC remain limited.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-5\"><jats:title>Objective<\/jats:title><jats:p>To estimate the incidence of neutropenia after IAC, as well as identify risk factors associated with the development of neutropenia.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This case series included pediatric patients with unilateral or bilateral retinoblastoma who were treated with IAC at a single quaternary care center from July 13, 2013, to January 6, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-7\"><jats:title>Exposure<\/jats:title><jats:p>All patients were treated with IAC and underwent multiple IAC cycles depending on treatment response. The primary chemotherapy agent used was melphalan, but topotecan or carboplatin could be used along with melphalan. Melphalan doses were kept to 0.4 mg\/kg or less per cycle. After each IAC cycle, complete blood cell counts were obtained within 10 to 12 days and repeated until the absolute neutrophil count (ANC) was greater than or equal to 1000\/\u03bcL.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the minimum ANC after each IAC cycle. The secondary outcome was the development of severe (grade 3 or 4) neutropenia (ANC &amp;amp;lt;1000\/\u03bcL). Regression analyses were used to identify associations between variables and outcomes. Receiver operating characteristic curves were used to calculate threshold dose for each chemotherapy agent potentially associated with the development of severe neutropenia.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-9\"><jats:title>Results<\/jats:title><jats:p>A total of 64 eyes of 49 patients (mean [SD] age, 1.7 [1.2] years; 25 females [51.0%]) with retinoblastoma were treated with 171 cycles of IAC. The mean (SD) nadir ANC was 1325.3 (890.7)\/\u03bcL and occurred a median (IQR) of 10 (10-14) days (range, 6-28 days) after IAC administration. The frequency distribution of post-IAC neutropenia grades 0, 1, 2, 3, 4, and missing was 31 (18.1% of cycles), 25 (14.6%), 40 (23.4%), 37 (21.6%), 26 (15.2%), and 12 (7.0%), respectively. Factors weakly correlated with a lower ANC were higher melphalan dose (\u03b2\u2009=\u2009\u22122356 [95% CI, \u20134120.6 to \u2212611.2]; adjusted <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.251; <jats:italic>P<\/jats:italic>\u2009=\u2009.01) and higher topotecan dose (\u03b2\u2009=\u2009\u22124056 [95% CI, \u20137003.6 to \u22121344.5]; adjusted <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.251; <jats:italic>P<\/jats:italic>\u2009=\u2009.006).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230065-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this case series of patients with retinoblastoma, the incidence of severe neutropenia after IAC was nearly 40%, which is higher than previously reported. Extended laboratory monitoring may aid in capturing previously overlooked cases of neutropenia. Topotecan may be associated with the development of neutropenia; limiting topotecan doses, especially in the setting of a high melphalan dose, may be beneficial in reducing the risk of neutropenia.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.4825","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T15:35:39Z","timestamp":1698939339000},"page":"1133","source":"Crossref","is-referenced-by-count":10,"title":["Incidence and Risk Factors for Neutropenia After Intra-Arterial Chemotherapy for Retinoblastoma"],"prefix":"10.1001","volume":"141","author":[{"given":"Debora H.","family":"Lee","sequence":"first","affiliation":[{"name":"Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Donkor","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew N.","family":"Parvus","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Dannenbaum","sequence":"additional","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Schefler","sequence":"additional","affiliation":[{"name":"Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston, Houston"},{"name":"Retina Consultants of Texas, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"eoi230065r2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2000.18.1.12","article-title":"Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma.","volume":"18","author":"Friedman","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"eoi230065r3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ajo.2005.03.037","article-title":"Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma.","volume":"140","author":"Wilson","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi230065r4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3341\/kjo.2010.24.4.219","article-title":"Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy.","volume":"24","author":"Shin","year":"2010","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"eoi230065r5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26270","article-title":"Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.","volume":"64","author":"Berry","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"eoi230065r6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/pbc.v60.4","article-title":"Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.","volume":"60","author":"Berry","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"eoi230065r7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v64.12","article-title":"Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.","volume":"64","author":"Berry","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"eoi230065r8","first-page":"577","article-title":"Complications of systemic chemotherapy as treatment of retinoblastoma.","volume":"118","author":"Benz","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"22","key":"eoi230065r9","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1002\/cncr.v118.22","article-title":"Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.","volume":"118","author":"Qaddoumi","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"eoi230065r10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10147-004-0392-6","article-title":"The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.","volume":"9","author":"Yamane","year":"2004","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"eoi230065r11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.ophtha.2007.12.014","article-title":"A phase I\/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.","volume":"115","author":"Abramson","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi230065r12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/archophthalmol.2011.5","article-title":"Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.","volume":"129","author":"Gobin","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"eoi230065r13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archophthalmol.2011.150","article-title":"Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.","volume":"129","author":"Shields","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi230065r14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/pbc.v60.5","article-title":"Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.","volume":"60","author":"Schaiquevich","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"eoi230065r15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ophtha.2018.05.013","article-title":"Ophthalmic vascular events after primary unilateral intra-arterial chemotherapy for retinoblastoma in early and recent eras.","volume":"125","author":"Dalvin","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi230065r16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/archophthalmol.2011.151","article-title":"Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications.","volume":"129","author":"Shields","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"eoi230065r17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/OPTH","article-title":"Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma.","volume":"5","author":"Vajzovic","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"eoi230065r18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v65.8","article-title":"Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina.","volume":"65","author":"Funes","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"eoi230065r19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4103\/ijo.IJO_843_16","article-title":"Intra-arterial chemotherapy for retinoblastoma: two-year results from tertiary eye-care center in India.","volume":"65","author":"Rishi","year":"2017","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"eoi230065r20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.oftal.2020.10.002","article-title":"Intra-arterial chemotherapy for retinoblastoma treatment in Chile: experience and results 2013-2020.","volume":"96","author":"Oporto","year":"2021","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"10","key":"eoi230065r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108692","article-title":"Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma.","volume":"9","author":"Dunkel","year":"2014","journal-title":"PLoS One"},{"issue":"20","key":"eoi230065r22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"eoi230065r23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"eoi230065r24","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The International Classification of Retinoblastoma predicts chemoreduction success.","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230065r25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MPH.0000000000002451","article-title":"Hematologic complications associated with intra-arterial chemotherapy for retinoblastoma treatment: a single institution experience.","volume":"44","author":"Sanati-Mehrizy","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"eoi230065r26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"10","key":"eoi230065r27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.mph.0000212996.94929.0b","article-title":"A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.","volume":"28","author":"Rondinelli","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"eoi230065r28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/mpo.v41:5","article-title":"Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.","volume":"41","author":"Ammann","year":"2003","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"eoi230065r29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ophtha.2013.10.045","article-title":"Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma.","volume":"121","author":"Taich","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230065r30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.3-1-4","article-title":"Clinical guidelines for managing topotecan-related hematologic toxicity.","volume":"3","author":"Armstrong","year":"1998","journal-title":"Oncologist"},{"issue":"9","key":"eoi230065r31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1634\/theoncologist.10-9-686","article-title":"Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.","volume":"10","author":"Armstrong","year":"2005","journal-title":"Oncologist"},{"key":"eoi230065r1","volume-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2020"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2811379\/jamaophthalmology_lee_2023_oi_230065_1702489048.15464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:01:56Z","timestamp":1703174516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2811379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.4825","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}